Vir-JPM-2025-Conference-Presentation

1January 14, 2025J.P. Morgan 2025 Healthcare Conference Confidential © 2024 Vir Biotechnology, Inc.Legal disclaimer2Forward-Looking StatementsStatements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: the therapeutic potential of Vir Biotechnology's oncology solid tumor portfolio, preclinical pipeline and PRO-XTENTM masked TCE platform, as well asVir Biotechnology's strategy, plans and expectations related thereto; the therapeutic potential ofVir Biotechnology'sCHD and CHBprograms, as well as Vir Biotechnology's strategy, plans and expectations related thereto;the potential of and Vir Biotechnology's expectations for its other pipeline programs;Vir Biotechnology's cash balance and anticipated cash runway;Vir Biotechnology'sclinical development plans and expectations for its oncology and hepatitis programs, includingprotocols for and enrollment into ongoing